Lexicon Pharmaceuticals | LXRX - Capitaux D'Emprunt





Capitaux D'Emprunt Changement Date
Abbott USD 29.64B 19.74B 2026-03
Acadia Pharmaceuticals USD 0 0 2025-03
Agios Pharmaceuticals USD 1.06M 0 2022-09
Akebia Therapeutics USD 48.25M 609K 2025-12
Alnylam Pharmaceuticals USD 2.48B 931K 2026-03
AstraZeneca USD 25.96B 177M 2026-03
BioMarin Pharmaceutical USD 1.43B 833.11M 2026-03
Coherus Biosciences USD 51.08M 496K 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Illumina USD 1.49B 0 2026-03
Insmed USD 540.96M 1.24M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
J&J USD 37.53B 1.91B 2026-03
Lexicon Pharmaceuticals USD 49.41M 7.1M 2025-12
MacroGenics USD 70M 256K 2025-12
MannKind USD 548.44M 244.79M 2025-12
Merck USD 46.67B 77M 2026-03
Moderna USD 603M 7M 2026-03
Novartis USD 37.45B 7.86B 2026-03
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
Thermo Fisher Scientific USD 40.07B 4.22B 2026-03
Ultragenyx Pharmaceutical USD 1.15B 383.26M 2025-12
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12